Comparison of Raloxifene and Isradipine Administration in Improvement of Schizophrenic Patients’ Cognitive Deficits.
- Conditions
- Condition 1: Schizophrenia. Condition 2: Schizoaffective,.Schizophrenia, schizotypal and delusional disorders
- Registration Number
- IRCT2016010225812N1
- Lead Sponsor
- Vice Chancellor for Research of Zanjan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria: All enrolled patients will have normal IQ ; systolic blood pressure more than 100 mmHg ; diastolic blood pressure more than 60 mmHg ; at least 2 years diagnosis of schizophrenia or schizoaffective disorder according to DSM-V diagnostic criteria.
patients with any other comorbidity of psychiatric or neurologic disorders ; history of lifetime substance abuse ; any sensitivity to drugs ; history of head trauma or loss of consciousness ; resistant high blood pressure ; resistance in treatment of schizophrenia or beginning Clozapine ; renal, liver or cardiac failure ; women' s pregnancy or breast feeding ; any abnormality in ECG ; suicide idea ; history of dementia ; breast cancer ; tromboemboli events ; dementia ; endocrine disease ; history of receiving ECT during last 12 months.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Attention. Timepoint: baseline and week 6. Method of measurement: The Stroop Color and Word test.;Executive Function. Timepoint: baseline and week 6. Method of measurement: The Wisconsin Card Sorting Test (WCST).;Processing Speed. Timepoint: baseline and week 6. Method of measurement: Wechsler Digit Coding Task, Symbol III.;Memory. Timepoint: baseline and week 6. Method of measurement: Wechsler, Verbal Memory test.;Structured Clinical Interview for the DSM-V (SCID). Timepoint: baseline and week 6. Method of measurement: Psychiatry resident will interview to confirm diagnosis for inclusion into study.
- Secondary Outcome Measures
Name Time Method PT, PTT, INR. Timepoint: baseline and week 6. Method of measurement: Blood sample.;LH, FSH, Vit D3. Timepoint: baseline and week 6. Method of measurement: blood sample.;Side effect self report form. Timepoint: Up to 6 weeks. Method of measurement: Patient report.;Change in ECG. Timepoint: Baseline and week 6. Method of measurement: ECG to confirm inclusion into study and compared at week 6 to baseline.;Change in chemistry panel ( TSH, T3, T4). Timepoint: Baseline and week 6. Method of measurement: Blood sample.;AST, ALT, ALKP. Timepoint: baseline and week 6. Method of measurement: Blood sample.